[Clinical characteristics and prognosis analysis of patients with IgG4-related hepatobiliary-pancreatic disease].

Zhonghua Gan Zang Bing Za Zhi

Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai200001, China.

Published: October 2024

To explore and analyze the clinical features of patients with immunoglobulin (Ig)G4-related hepatobiliary-pancreatic disease and the independent factors affecting the prognosis of IgG4-related sclerosing cholangitis (IgG4-SC). The clinical data of 179 adult cases diagnosed with IgG4-related hepato-pancreato-biliary disease in the Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 2011 to December 2022 were retrospectively analyzed. Patients were divided into three groups: isolated IgG4-SC, IgG4-SC/type 1 autoimmune pancreatitis(type 1 AIP), and isolated AIP according to the clinical manifestations. Demographic characteristics, baseline biochemical immunological indexes, and imaging manifestations were analyzed. The treatment response rate and survival rate were compared. The COX proportional hazards model was used to analyze the independent factors related to prognosis. The mean age of diagnosis of patients with IgG4-related hepatobiliary-pancreatic disease was 60.3±12.0 years. Males accounted for 74.9%, and the median follow-up time was 38 months. The 1-year clinical response rate of patients with isolated IgG4-SC was lower than that of IgG4-SC/AIP (67.9% vs. 91.7%, =0.019), and the primary endpoint-free 5-year survival rate was significantly reduced (64.9% vs. 95.9%, <0.001). COX regression analysis showed that having cirrhosis before treatment (=6.708, =0.004) and poor response after half a year of treatment (=11.488, =0.002) were independent risk factors associated with the occurrence of adverse events in hepatobiliary diseases among patients with IgG4-SC. The clinical response rate and survival rate of patients with isolated IgG4-SC are lower than those of patients with IgG4-SC/AIP. Patients with IgG4-SC who do not respond well at six months of treatment and who have progressed to cirrhosis before treatment are at significantly increased risk of adverse events.

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn501113-20230828-00073DOI Listing

Publication Analysis

Top Keywords

igg4-related hepatobiliary-pancreatic
12
patients igg4-related
8
hepatobiliary-pancreatic disease
8
independent factors
8
factors prognosis
8
isolated igg4-sc
8
response rate
8
survival rate
8
patients
5
igg4-related
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!